Discover
ELVN
Enliven Therapeutics, Inc.
49.45
2 x 36.36
2 x 63.78
bid
ask
-
0.79
1.57%
2 @ 07:40 PM
49.45 +0.00 (0.01%)
| Ytd | 221.10% | |
| 1y | 148.24% |
49.20
day range
51.20
15.14
52 week range
61.15
| Open | 49.43 | Prev Close | 50.24 | Low | 49.20 | High | 51.20 | Mkt Cap | 3.62B |
| Vol | 6.01M | Avg Vol | 1.21M | EPS | -1.65 | P/E | N/A | Forward P/E | -21.15 |
| Beta | 0.24 | Short Ratio | 8.31 | Inst. Own | 113.91% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 56.32 | 200-d Avg | 38.93 | 1yr Est | 73.90 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-11-11 | 2026-09 | -0.43 | N/A | N/A | N/A |
| 2026-08-05 | 2026-06 | -0.39 | -0.49 | -0.1 | -26.56% |
| 2026-05-07 | 2026-03 | -0.44 | -0.38 | 0.06 | 13.64% |
| 2026-03-03 | 2025-12 | -0.42 | -0.48 | -0.06 | -14.29% |
| 2025-11-12 | 2025-09 | -0.43 | -0.32 | 0.11 | 25.58% |
| 2025-08-13 | 2025-06 | -0.53 | -0.49 | 0.04 | 7.55% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-08-18 | William Blair | Upgrade | Outperform | |
| 2026-08-18 | Barclays | Upgrade | Overweight | |
| 2026-08-18 | Mizuho | Upgrade | Outperform | Outperform |
| 2026-08-06 | Stifel | Upgrade | Buy | Buy |
| 2026-08-06 | Guggenheim | Upgrade | Buy | Buy |
| 2026-08-06 | Goldman Sachs | Upgrade | Buy | Buy |
Profile
Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-10-07 | BALLAL RAHUL D. | Director | 22.34K | Sale |
| 2026-08-16 | COLLINS HELEN LOUISE | Officer | 25.00K | Sale |
| 2026-08-03 | DERYNCK MIKA K | Director | 0.00 | Sale |
| 2026-02-16 | HEYMAN RICHARD A | Director | 0.00 | Sale |
| 2026-08-16 | HOHL BENJAMIN | Chief Financial Officer | 40.04K | Sale |
| 2025-11-16 | KINTZ SAMUEL | Chief Executive Officer | 0.00 | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | FMR, LLC | 10.03M | 495.74M | 13.68% |
| 2026-06-29 | Orbimed Advisors LLC. | 6.78M | 335.10M | 9.25% |
| 2026-06-29 | Polar Capital Holdings PLC | 6.43M | 317.99M | 8.78% |
| 2026-06-29 | Blackrock Inc. | 4.36M | 215.59M | 5.95% |
| 2026-06-29 | Vestal Point Capital, LP | 4.00M | 197.80M | 5.46% |
| 2026-06-29 | Commodore Capital Lp | 3.28M | 161.95M | 4.47% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-06-29 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 1.88M | 93.13M | 2.57% |
| 2026-07-30 | Fidelity Select Portfolios-Select Health Care Portfolio | 1.34M | 66.26M | 1.83% |
| 2026-06-29 | Fidelity Securities Fund-Fidelity Small Cap Growth Fund | 1.25M | 61.85M | 1.71% |
| 2026-07-30 | iShares Trust-iShares Russell 2000 ETF | 1.09M | 54.05M | 1.49% |
| 2026-06-29 | T. Rowe Price New Horizons Fund, Inc. | 807.33K | 39.92M | 1.10% |
| 2026-07-30 | Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 747.60K | 36.97M | 1.02% |